Individual investors invested in Laurus Labs Limited (NSE:LAURUSLABS) up 4.6% last week, insiders too were rewarded
Key Insights
- The considerable ownership by individual investors in Laurus Labs indicates that they collectively have a greater say in management and business strategy
- 50% of the business is held by the top 13 shareholders
- Insider ownership in Laurus Labs is 28%
A look at the shareholders of Laurus Labs Limited (NSE:LAURUSLABS) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 39% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
While individual investors were the group that reaped the most benefits after last week’s 4.6% price gain, insiders also received a 28% cut.
Let's take a closer look to see what the different types of shareholders can tell us about Laurus Labs.
See our latest analysis for Laurus Labs
What Does The Institutional Ownership Tell Us About Laurus Labs?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
Laurus Labs already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Laurus Labs, (below). Of course, keep in mind that there are other factors to consider, too.
Hedge funds don't have many shares in Laurus Labs. With a 23% stake, CEO Satyanarayana Chava is the largest shareholder. With 6.5% and 3.2% of the shares outstanding respectively, Capital Research and Management Company and Anukar Projects Private Limited are the second and third largest shareholders.
After doing some more digging, we found that the top 13 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Laurus Labs
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own a reasonable proportion of Laurus Labs Limited. It is very interesting to see that insiders have a meaningful ₹121b stake in this ₹428b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 39% stake in Laurus Labs. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
We can see that Private Companies own 4.5%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for Laurus Labs you should be aware of.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:LAURUSLABS
Laurus Labs
Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.
Excellent balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Community Narratives
